My Top Two Stocks: InvenSense and Infinera

Before you go, we thought you'd like these...
Before you go close icon

In this video, Fool.com contributors John Reeves and David Meier sit down and talk about the two biggest holdings in David's portfolio. He shares with investors how his investing style has shifted over the years, and why InvenSense and Infinera both represent incredible disruptive opportunities, and why he sees them as two of the next great companies on the market.

Are you still on the search for those cornerstone stocks that belong in your portfolio both today and forever? Motley Fool CEO and investing maverick Tom Gardner is now sharing his two highest-conviction stock picks ever with you. They're the biggest positions in his Everlasting Portfolio, which are the only stocks he's buying for the rest of his life. Tom has crushed Wall Street for years, and today you're invited to uncover his top picks for FREE. To learn more about these lifelong-worthy stocks and how to benefit from Tom's market-stomping service, just click here now.


The article My Top Two Stocks: InvenSense and Infinera originally appeared on Fool.com.

David Meier owns shares of MAKO Surgical, InvenSense, and Infinera. John Reeves has no position in any stocks mentioned. The Motley Fool recommends Infinera and MAKO Surgical. The Motley Fool owns shares of Infinera and InvenSense. The Motley Fool is short InvenSense. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners